CCL13 and atherosclerosis: Earlier on, a study of adipokines in obesity and related comorbidities suggests that CCL13, a brand-new biomarker for extreme obesity, may exacerbate subclinical atherosclerosis in persons with obesity by affecting circulating levels of major atherosclerotic markers.